Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) was valued at US$ 13,900.0 million in 2017 and is estimated to exhibit a CAGR of 8.4% over the forecast period (2018-2026).
The increasing number of people suffering from early stage of Alzheimer’s disease with dementia do not have proper access to healthcare infrastructure for diagnosis and treatment of the disease, globally. For instance, according to the World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle-income economies, and this is expected to drive growth of the dementia drugs market over the forecast period. Moreover, as of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis and develop treatment for Alzheimer’s disease.
Get FREE Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables and Figures) of Dementia Drugs, https://www.coherentmarketinsights.com/insight/request-sample/1664
The market is expected to witness significant growth over the forecast period, attributed to advancing diagnostic capabilities and growing awareness about dementia, among populace. Moreover, disease-modifying mechanisms are expected to enhance the treatment of this neurodegenerative condition. As a global push is made for early diagnosis and treatment, the surge in dementia cases will require effective therapies. Furthermore, market players are increasingly focusing on receiving the FDA approvals for their products, which is further expected to boost the market growth over the forecast period. For instance, in September 2017, Zydus Cadila received approval from the U.S. FDA to market Donepezil Hydrochloride tablets used for the treatment of dementia of the Alzheimer’s type in the U.S.
In addition, several market players are focusing on developing novel drugs, in order to strengthen their market position, globally. For instance, in 2016, Merck and Company bought an exclusive worldwide license from Japan’s Teijin Pharma to develop an investigational, preclinical anti-tau antibody, which has disease-modifying potential. Similarly, Genentech and AC immune are developing anti-tau antibody. Furthermore, in 2017, TauRx announced phase three results of investigational drug LMTX first tau aggregation inhibitor for Alzheimer’s disease.
Browse 25 Market Data Tables and 44 Figures spread through 173 Pages and in-depth TOC on “Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) – Global Forecast to 2026”
To know the latest trends and insights related to dementia drugs market Press Release, click the link below: https://bit.ly/3aVcvHp
Moreover, increasing product approvals by regulatory agencies is expected to boost the market growth over the forecast period. For instance, in January 2018, FDA proposed new guidelines aimed at lowering the clinical study goals of Alzheimer’s disease drugs for treating earlier-stage patients, who have not showed functional disability or clinical abnormality. This is part of efforts to expand access to safe and effective treatment options for serious conditions, including Alzheimer’s disease through accelerated approval for such drugs.
However, failure of drugs in late stages of clinical trials is the major factor that is expected to hinder growth of the market over the forecast period. For instance, in 2012, Pfizer Inc. and Johnson & Johnson, announced to discontinue the development of Alzheimer drug, which was in intravenous (IV) form—bapineuzumab, as the drug failed to help patients with memory robbing condition in a second high profile clinical trial.
Moreover, dementia drugs market faces challenges, while expanding in certain regions. For instance, in the U.K., issues related to cost-effectiveness of cholinesterase inhibitors impelled the Clinical Excellence and National Institute of Health to edge reimbursements to patients with moderate AD. Additionally, they limit the prescriptions of moderate AD valid only through neurologists, which are usually referred to the patients at later disease stage. Thus, adoption of these drugs are low in Europe. However, disease-modifying drugs may gain traction in this region in near future.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1664
Key takeaways of the dementia drugs market:
- The global dementia drugs market is expected to exhibit a CAGR of 8.4% over the forecast period (2018-2026). This is attributed to increasing incidence of dementia, across the globe especially in Asia Pacific, coupled with increasing number of government initiatives to provide better palliative care to patients.
- Among drug class, MAO inhibitors segment is expected to witness significant growth over the forecast period, owing to monoamine oxidase-B (MAO-B) inhibitor, which is less toxic compared to cholinesterase inhibitor and has a concomitant extension of life span
- Key players operating in the global dementia drugs market include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd, among others
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
